SECOND TEAM Glen Santangelo  Credit Suisse

Clients say “timely updates” and “a thorough understanding of the strengths and weaknesses of the companies he covers” help Glen Santangelo advance from third place to second. The Credit Suisse analyst highlighted his buy call on McKesson Corp. in mid-December, at $68.91, on the belief that the San Francisco–based pharmaceuticals wholesaler’s profits would rise following its takeover of U.S. Oncology. (That deal was completed on December 30.) In July the company reported a 9.2 percent increase in revenue, to $29.98 billion, for its fiscal first quarter, which ended June 30; analysts had forecast revenues of $29.04 billion for the three-month period. By the end of August, McKesson’s stock had surged 16 percent, to $79.93, since Santangelo’s reiteration.